| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. | TNX-4800 (mAb 2217LS) | Lyme Disease | Phase 2/3 | Trial Planned | Intramuscular | N/A |
| Tonix Pharmaceuticals Holding Corp. | TNX-102 SL - (OASIS) | Acute stress reaction (ASR), acute stress disorder (ASD), and posttraumatic stress disorder (PTSD) | Phase 2 | Ongoing | Sublingual | Psychiatric |
| Tonix Pharmaceuticals Holding Corp. | TNX-1300 - (CATALYST) | Drug overdose | Phase 2 | Trial Discontinued | Intravenous | N/A |
| Tonix Pharmaceuticals Holding Corp. | TNX-1900 - (DoD trial, BOX) | Bone health in Children with Autism Spectrum Disorder (ASD) | Phase 2 | Ongoing | intranasal | Genetic Disorder |
| Tonix Pharmaceuticals Holding Corp. | TNX-1900 - (STROBE) | Binge-Eating Disorder | Phase 2 | Ongoing | Intranasal | Psychiatric |
| Tonix Pharmaceuticals Holding Corp. | TNX-1900 - (University of Washington trial) | Social anxiety disorder (SAD) | Phase 2 | Ongoing | Intranasal | Psychiatric |
| Tonix Pharmaceuticals Holding Corp. | TNX-1900 - (POWER) | Pediatric obesity related binge eating disorder | Phase 2 | Ongoing | Intranasal | Psychiatric |
| Tonix Pharmaceuticals Holding Corp. | TNX-3500 | Long Covid-19 | Phase 2 | Trial Planned | Intravenous | COVID-19 |